Blood (journal)

June 25, 2024

International trial introduces another curative option for sickle cell disease 

The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.

By Jessica Pasley
The research team included, from left, Hannah Poisner, Sydney Olson, J. Brett Heimlich, MD, PhD, Ningning Hu, MS, Alyssa Parker, Alexander Bick, MD, PhD, Joseph Van Amburg and Tara Mack.
February 2, 2023

Researchers clarify role of blood cell mutations in disease

Vanderbilt researchers have developed a new method to analyze mutations in blood stem cells that can trigger explosive, clonal expansions of abnormal cells.

By Bill Snyder
January 31, 2019

Cell death pathway implicated in bone marrow failure

Vanderbilt investigators have linked a specific form of programmed cell death to myelodysplastic syndrome, a type of bone marrow failure.

By Leigh MacMillan
April 12, 2012

Targeting post-transplant diabetes

Targeting diabetes that develops after a stem cell transplant may help moderate graft-vs.-host disease, an adverse effect of the procedure, and improve outcomes.

By VUMC News and Communications